Private Equity's Inversion Excursion: Pepper Hamilton Talks Tax With the Deal

more+
less-
In this interview with The Deal’s Jon Marino, Pepper Hamilton LLP's Joan Arnold, a partner who heads the firm's tax group, says Pfizer’s play for AstraZeneca isn’t the only inversion deal being sought. There are no shortages of U.S. companies looking to buy a foreign asset and re-incorporate itself overseas to save on American tax bills. There are private equity firms, as well, that may consider making smaller moves to save a bundle on tax obligations as well. Elsewhere, in other sectors, investors in InterContinental Hotels Group See more +
In this interview with The Deal’s Jon Marino, Pepper Hamilton LLP's Joan Arnold, a partner who heads the firm's tax group, says Pfizer’s play for AstraZeneca isn’t the only inversion deal being sought. There are no shortages of U.S. companies looking to buy a foreign asset and re-incorporate itself overseas to save on American tax bills. There are private equity firms, as well, that may consider making smaller moves to save a bundle on tax obligations as well. Elsewhere, in other sectors, investors in InterContinental Hotels Group want that company to sell itself to a U.S. buyer, in another potential inversion deal. See less -

Embed Video

Copy

Topics:  Acquisitions, AstraZeneca, Corporate Taxes, Hotels, Inversion, Pfizer, Popular, Private Equity

Published In: Business Organization Updates, Finance & Banking Updates, International Trade Updates, Tax Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Pepper Hamilton LLP | Attorney Advertising

Other Videos by Pepper Hamilton LLP